Evidence map›Paper›PMID 39124724›Full record

ReviewJournal of clinical medicine2024

New Frontiers in Locally Advanced Cervical Cancer Treatment.

Roberta Massobrio, Lavinia Bianco, Beatrice Campigotto, Daniela Attianese, Elisa Maisto, Maria Pascotto, Maria Grazia Ruo Redda, Annamaria Ferrero

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Roberta MassobrioAcademic Division of Gynecology and Obstetrics, University of Turin, Mauriziano Umberto I Hospital, 10128 Turin, Italy.ORCID 0000-0003-4172-0840
Lavinia BiancoDepartment of Radiation Oncology, University of Turin, Mauriziano Umberto I Hospital, 10128 Turin, Italy.
Beatrice CampigottoAcademic Division of Gynecology and Obstetrics, University of Turin, Mauriziano Umberto I Hospital, 10128 Turin, Italy.
Daniela AttianeseAcademic Division of Gynecology and Obstetrics, University of Turin, Mauriziano Umberto I Hospital, 10128 Turin, Italy.ORCID 0009-0005-9263-9227
Elisa MaistoAcademic Division of Gynecology and Obstetrics, University of Turin, Mauriziano Umberto I Hospital, 10128 Turin, Italy.
Maria PascottoAcademic Division of Gynecology and Obstetrics, University of Turin, Mauriziano Umberto I Hospital, 10128 Turin, Italy.
Maria Grazia Ruo ReddaDepartment of Radiation Oncology, University of Turin, Mauriziano Umberto I Hospital, 10128 Turin, Italy.
Annamaria FerreroAcademic Division of Gynecology and Obstetrics, University of Turin, Mauriziano Umberto I Hospital, 10128 Turin, Italy.ORCID 0000-0002-2909-3699

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the introduction of targeted vaccines and screening protocols, locally advanced cervical cancer represents a median proportion of 37% among all cervical carcinomas. Compared to early stages, it presents significantly lower cure rates, with a 5-year disease-free survival rate of 68% and a 5-year overall survival rate of 74%. According to current guidelines, definitive radiotherapy with concomitant chemotherapy represents the gold standard for locally advanced cervical cancer treatment. However, a significant number of patients relapse and die from metastatic disease. The aim of this narrative review is to examine the recent advancements in treating locally advanced cervical cancer, exploring new frontiers in therapeutic approaches. The PubMed database and clinical trial registries were searched to identify relevant articles published on locally advanced cervical cancer treatment up to March 2024, mainly focusing on papers published in the last decade. Abstracts presented at major international congresses that bring relevant evidence were included. Progress achieved in refining radiotherapy techniques, recent evidence regarding neoadjuvant treatment preceding surgery or concurrent chemoradiotherapy, and key findings concerning adjuvant treatment are thoroughly explored. Furthermore, a comprehensive review of prominent phase II and phase III trials examining the integration of immune checkpoint inhibitors is conducted, analyzing the various contexts in which they are applied. In light of the new evidence that has emerged in recent years and is discussed in this article, the appropriate selection of the most suitable therapeutic approach for each patient remains a complex but crucial issue.

Indexed as

adjuvant chemotherapychemoradiation therapyimmune checkpoint inhibitorsimmunotherapylocally advanced cervical cancerneoadjuvant chemotherapy

Identifiers

PMID39124724
PMCPMC11312973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.